VivoSeq
Infectious Disease

Coronavirus

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Coronavirus is an early-stage landscape with 1 program across 2 companies. The most active players are Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Takeda.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

43/100

Attrition Rate

38/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. logo

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

CYNK-001

Celularity Incorporated

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

21

clinical trials

Terminated6 · 29%
Unknown status6 · 29%
Completed6 · 29%
Withdrawn2 · 10%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

Pancoronavirus Vaccine Study in Healthy Adults
Active, not recruiting·—·Phase 1·NCT06950177·51 enrolled
Convalescent Plasma to Stem Coronavirus (CSSC-001)
Completed·JJohns Hopkins University·Phase 2·NCT04323800·180 enrolled
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus
Completed·SSENAI CIMATEC·Phase 2·NCT05446961·224 enrolled
Remdesivir Efficacy in Coronavirus Disease
Completed·TTanta University·Phase 2/3·NCT04345419·200 enrolled
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV
Completed·FFundación Huésped·Phase 2·NCT05005156·155 enrolled
Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Completed·Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. logoAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.·N/A·NCT05850507·450 enrolled
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
Completed·FFundación Huésped·Phase 2·NCT05293223·88 enrolled
Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?
Terminated·—·Phase 3·NCT04374942·13 enrolled
Colchicine in Patients With Mild and Severe Coronavirus Disease
Terminated·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT04367168·116 enrolled
VA CoronavirUs Research and Efficacy Studies-1
Terminated·VVA Office of Research and Development·Phase 3·NCT04539275·75 enrolled
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
Terminated·MMontreal Heart Institute·Phase 3·NCT04322682·4,506 enrolled
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
Terminated·EEmory University·Phase 3·NCT05946551·5 enrolled
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
Terminated·CCelularity Incorporated·Preclinical·NCT04365101·7 enrolled
SARS Coronavirus Vaccine (SARS-CoV)
Withdrawn·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00533741
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
Withdrawn·Takeda logoTakeda·Phase 1·NCT04464460
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)